Zeke Capital Advisors’s UroGen Pharma URGN Stock Holding History

Zeke Capital Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-180,000	Closed	-$1.57M	–	536
2022 Q1	$1.57M	Sell	180,000 -413,656	-70%	-$3.23M	0.08%	106
2021 Q4	$5.65M	Sell	593,656 -130,021	-18%	-$1.83M	0.33%	34
2021 Q3	$12.2M	Buy	723,677 +802	+0.1%	+$12.7K	0.7%	29
2021 Q2	$11M	Buy	722,875 +205,769	+40%	+$3.72M	0.7%	33
2021 Q1	$10.1M	Buy	+517,106	New	+$11M	0.7%	31

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Zeke Capital Advisors's URGN Position: Q2 2022 in Review

Zeke Capital Advisors sold out of UroGen Pharma (URGN) in Q2 2022, closing a stake of 180,000 shares — an estimated $1.57M sold.

Zeke Capital Advisors first reported a position in URGN in Q1 2021 and held it in 5 quarters. The position peaked at $12.2M in Q3 2021. 65 funds tracked by Wall St. Rank hold URGN as of Q2 2022.

Zeke Capital Advisors reported no remaining UroGen Pharma position as of Q2 2022 after selling out during the quarter.
Zeke Capital Advisors sold 180,000 UroGen Pharma shares in Q2 2022, an estimated $1.57M.
Zeke Capital Advisors first reported a position in UroGen Pharma in Q1 2021 and held it in 5 quarters.
Zeke Capital Advisors's UroGen Pharma position peaked at $12.2M in Q3 2021.
65 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2022.

Based on Zeke Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.